Zurück zu den Rankings

ICU Medical, Inc. (ICUI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

49

Kurs

$183.10

Marktkapitalisierung

$4.55B

Teil 1 · Was das Unternehmen wert ist

Übersicht

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilanz & Liquidität

Umsatz

$2.16B

Letzte 12 Monate (bis 30.6.2026)

Nettogewinn

$30M

Letzte 12 Monate (bis 30.6.2026)

Freier Cashflow

$92M

Gesamtes Eigenkapital

$2.12B

Gesamtverbindlichkeiten

$1.93B

Current Ratio

2.43

Zinsdeckungsgrad

0.87

Schulden/EBITDA

5.28

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

General caseÜberbewertet

Innerer Wert

$102.68

Aktueller Kurs

$183.10

Sicherheitsmarge

-78.3%

Innerer-Wert-Spanne

$66.74 - $138.62

Bewertungsmethoden

Analyst price target:$193.38
Discounted cash flow (DCF):$117.21
Earnings multiple (P/E):$22.75
Graham growth formula:$8.90
Earnings power value (EPV):$29.87
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$234.96
Revenue multiple:Not enough data to compute it
Analystenkonsens:Starker Kauf (12B / 1H / 0S)
Letzte Gewinnüberraschung:+21.43%

Bewertungskennzahlen

P/E-Verhältnis

153.40

ROE

0.0%

P/B-Verhältnis

2.12

P/FCF

29.87

Bruttomarge

39.1%

ROIC

1.6%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

1.6%

WACC

8.5%

ROIC − WACC

-6.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamentalanalyse-Kriterien

Bestanden (14)

  • Gross Margin 39.1%
  • P/FCF 29.87
  • P/B Ratio 2.12
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Revenue Growth 5Y 11.9%
  • Analyst Consensus 92% Buy
  • Earnings Surprise avg 20.3%
  • Earnings Quality (OCF/NI) 7.86
  • Share Dilution 0.1%
  • Net Margin Trend 1.4% vs -1.6%
  • Piotroski F-Score 7/9

Nicht bestanden (12)

  • EPS shows upward trend
  • EPS CAGR -19.56%
  • Price CAGR 2.18%
  • ROIC 1.6%
  • Operating Margin 3.3%
  • CapEx intensity
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.2%

Nicht verfügbar (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

7/9

Starke finanzielle Gesundheit

score
criteria

Gewinnqualität

7.86

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

0.1%

Aktienanzahl ist stabil

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Vivek JainCEO & Chairman of the Board53
Mr. Daniel WoolsonPresident48
Mr. Brian Michael BonnellCFO & Treasurer51
Mr. Christian B. VoigtlanderChief Operating Officer57
Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer50
Ben SousaChief Information Officer-
Olivia BarrallVice President of Human Resources-

Prüfungsrisiko

5

Vorstandsrisiko

4

Vergütungsrisiko

4

Aktionärsrechterisiko

5

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for ICUI, sourced from Markets Gazette.

No recent news for ICUI.